CorMedix (NYSEAMERICAN:CRMD) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a research report issued on Thursday.

According to Zacks, “CorMedix Inc. is a development-stage pharmaceutical company that seeks to in-license, develop and commercialize therapeutic products for the treatment of cardiac and renal dysfunction, also known as cardiorenal disease. CorMedix’s goal is to treat kidney disease by reducing the commonly associated cardiovascular and metabolic complications. The Company’s therapeutic candidates for cardiorenal disease may be small molecules, biologicals, devices and/or diagnostics (tests) that enable therapy. Its product pipeline includes: CRMD001, a unique formulation Deferiprone which is in development to prevent Contrast-Induced Acute Kidney Injury and to slow progression of Chronic Kidney Disease; CRMD002, a diagnostic test for urinary labile iron; CRMD003 (Neutrolin┬«, an antimicrobial/anticoagulant solution) is in development to prevent Catheter Related Bloodstream Infection; CRMD004, a pressure sensitive gel which has many uses, including extending the benefits of Neutrolin┬«. CorMedix Inc. is based in Summit, New Jersey. “

How to Become a New Pot Stock Millionaire

Shares of CorMedix stock traded up $0.01 during trading on Thursday, reaching $0.31. 1,419,246 shares of the company’s stock were exchanged, compared to its average volume of 1,561,303. The company has a market cap of $18.50, a price-to-earnings ratio of -0.51 and a beta of 0.60. CorMedix has a 1-year low of $0.27 and a 1-year high of $1.91.

A number of institutional investors have recently made changes to their positions in CRMD. Virtu Financial LLC grew its holdings in CorMedix by 126.4% in the 4th quarter. Virtu Financial LLC now owns 226,748 shares of the biotechnology company’s stock worth $114,000 after acquiring an additional 126,610 shares during the last quarter. Spinnaker Capital LLC bought a new stake in shares of CorMedix during the 4th quarter valued at about $202,000. Finally, Vanguard Group Inc. boosted its stake in shares of CorMedix by 3.0% during the 2nd quarter. Vanguard Group Inc. now owns 1,208,894 shares of the biotechnology company’s stock valued at $518,000 after purchasing an additional 35,148 shares in the last quarter.

TRADEMARK VIOLATION WARNING: “CorMedix (CRMD) Downgraded by Zacks Investment Research to “Hold”” was originally published by Watch List News and is the property of of Watch List News. If you are reading this news story on another site, it was stolen and republished in violation of US and international copyright & trademark laws. The correct version of this news story can be viewed at https://www.watchlistnews.com/cormedix-crmd-downgraded-by-zacks-investment-research-to-hold/1958144.html.

CorMedix Company Profile

CorMedix Inc is a commercial pharmaceutical and medical device company. The Company in-licenses, develops and commercializes prophylactic and therapeutic products for the prevention and treatment of infectious and inflammatory diseases. The Company has in-licensed the rights to develop and commercialize its product candidate, CRMD003 (Neutrolin), which addresses market opportunities in the instances in which a central venous catheter is used, such as hemodialysis, intensive care units, oncology, and patients receiving total parenteral nutrition, intravenous (IV) hydration, and/or IV medications.

Get a free copy of the Zacks research report on CorMedix (CRMD)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for CorMedix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CorMedix and related companies with MarketBeat.com's FREE daily email newsletter.